TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Henry Schein Inc (HSIC)

Healthcare Medical Distribution
85.80 $
+0.7% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Henry Schein Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 8 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
85.20$
Open
84.80$
Day High
86.30$
Day Low
84.40$
Volume
1,168,642shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
62.00 $ 88.30 $
10/16/2025 07/16/2026

Current price 85.80 $ — 91% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
9.6$B
Shares Outstanding
114Mio.
Float
82.4%
Beta
0.8

Performance

Perf. 1M
10.40%
Perf. 3M
16.90%
Perf. 6M
10.60%
YTD Performance (%)
6.00%
52-Week-High Distance
-6.3%
Perf. 1Y
26.76%
Perf. 3Y
8.83%
Perf. 5Y
6.99%
Perf. 10Y
20.88%
Perf. Since Inception
1,823.29%

Technical Indicators

MA 38 Days
83.80$
MA 50 Days
81.80$
MA 200 Days
76.30$
RSI (14)
55.8
Volatility 30 Days
23.2%
Volatility 250 Days
27.2%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
26.3
Forward P/E
16.0
PEG
1.8
P/B
3.0
P/S
0.7
EV/EBITDA
13.6
Price/FCF
22.3

Profitability

Gross Margin
31.2%
EBIT Margin
5.9%
Net Margin
2.9%
Return on Equity
8.8%
Return on Assets
4.4%

Balance Sheet & Safety

Equity Ratio
28.9%
negative equity
Debt/Equity
-3.7
Altman Z″
5.84
weak
Piotroski
2 out of 9

Growth

Sales Growth Last Quarter
6.30%
EPS Growth Last Quarter
4.50%
Sales Growth (Year)
4.03%
Forward Sales Growth
3.76%
Forward EPS Growth
10.60%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
RS Rating
48
EPS Rating
54
weak
Piotroski
2 out of 9
Fundamental Rating
C (47 out of 100)
Altman Z″
5.84

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Growth Score

3 of 10 Weak growth

Ten checks against the annual reports — each one passed counts a point.

  • Revenue grows by more than 15% a year over three years 1.4% failed
  • More than 10% revenue growth is expected for the coming year 3.8% failed
  • Share count grows by less than 3% a year -4.0% passed
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 8.4% failed
  • Gross margin at 40% or higher and without meaningful erosion 29.1% failed
  • Goodwill from acquisitions does not grow faster than revenue 37.6% failed
  • Net debt below twice EBITDA 3.5 x EBITDA failed
  • Operating cash flow covers the profits of the last three years 856 m passed
  • Return on capital at 15% or higher, or up versus two years ago 9.5% passed
  • Insiders hold at least 10% or are net buyers 0.8% failed

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 85.80 $
Price Target (average) 89.31 $

The price target sits 4.1% above the current price.

Consensus
Hold
Analyst Ratings
16
Distribution of Recommendations
Strong Buy 3
Buy 4
Hold 8
Sell 0
Strong Sell 1

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 5.34 5.25 – 5.45 13,745 7.5% 17
12/31/2027 5.91 5.74 – 6.19 14,254 10.5% 17

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

4. Aug 2026 · before the open · Q2 2026
Expected Earnings per Share
1.22 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 3,191.0 $M Q4 2025: Q1 · 3,168.0 $M Q1 2025: Q2 · 3,240.0 $M Q2 2025: Q3 · 3,339.0 $M Q3 2025: Q4 · 3,437.0 $M Q4 2026: Q1 · 3,368.0 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.75 443.50 3,191 5.80 2.90 204 159
2025: Q1 0.88 22.90 3,168 -0.10 3.50 37 -6
2025: Q2 0.70 -13.30 3,240 3.30 2.70 120 88
2025: Q3 0.83 7.10 3,339 5.20 3.00 174 141
2025: Q4 0.85 14.10 3,437 7.70 2.90 381 338
2026: Q1 0.92 4.60 3,368 6.30 3.20 -97 -136
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 11,572 817 507 3.12 615 2,793 6,760
2017 12,462 865 406 2.57 546 2,812 7,864
2018 13,202 693 536 3.49 685 2,961 8,501
2019 9,986 733 508 3.40 654 2,998 7,151
2020 10,119 567 402 2.80 599 3,348 7,773
2021 12,401 855 624 4.40 710 3,425 8,481
2022 12,647 938 538 3.91 602 3,446 8,607
2023 12,339 714 416 3.16 500 3,655 10,573
2024 12,673 729 390 3.05 848 3,393 10,218
2025 13,184 758 398 3.27 712 3,245 11,215

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Henry Schein, Inc. bietet weltweit Gesundheitsprodukte und -dienste für niedergelassene Zahn- und Allgemeinmediziner an.

Employees25,000
HeadquartersMelville, NY
Address135 Duryea Road, 11747 Melville, United States
Phone631 843 5500
Websitehenryschein.com
IPO Date3. Nov 1995
ISINUS8064071025
Stock Split1275:1000 on 02/08/2019

Management

Management
Name Title Birth Year
Ronald N. South Senior VP & CFO 1962
Michael Saul Ettinger Executive VP & COO 1961
Mark E. Mlotek Executive VP & Chief Strategic Officer 1956
Andrea Albertini Chief Executive Officer of Global Distribution & Technology 1970
Frederick M. Lowery CEO & Director 1971
Olga Timoshkina VP of Corporate Finance & Chief Accounting Officer
Christopher Pendergast Senior VP & CTO 1963
Graham Stanley VP of Investor Relations & Strategic Finance Project Officer
Kelly Murphy J.D. Senior VP & General Counsel 1981
Christine Sheehy Senior VP & Chief Human Resources Officer 1968

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?